1220034-97-8

Basic information

• Product Name: (4-Benzyl-1-piperazinyl)(4-piperidinyl)methanonehydrochloride
• Synonyms: (4-Benzyl-1-piperazinyl)(4-piperidinyl)methanonehydrochloride;(4-BENZYLPIPERAZIN-1-YL)(PIPERIDIN-4-YL)METHANONE HYDROCHLORIDE
• CAS NO: 1220034-97-8
• Molecular Formula: C₁₇H₂₅N₃O*ClH
• Molecular Weight: 323.86084
• Mol File: 1220034-97-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-Benzyl-1-piperazinyl)(4-piperidinyl)methanonehydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Benzyl-1-piperazinyl)(4-piperidinyl)methanonehydrochloride(1220034-97-8)
• EPA Substance Registry System: (4-Benzyl-1-piperazinyl)(4-piperidinyl)methanonehydrochloride(1220034-97-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1220034-97-8(Hazardous Substances Data)

Usage

General Description

(4-Benzyl-1-piperazinyl)(4-piperidinyl)methanonehydrochloride is a chemical compound that consists of a piperazine ring with a benzyl group and a piperidine ring attached to a methanone group. It is commonly used as a pharmaceutical intermediate in the synthesis of various medications, including psychoactive drugs and antipsychotics. The hydrochloride salt form of this compound makes it more stable and soluble, making it easier to handle and use in research and manufacturing processes. (4-Benzyl-1-piperazinyl)(4-piperidinyl)methanonehydrochloride has potential applications in the pharmaceutical industry for the development of new medications targeting various neurological and psychiatric disorders.

Relevant articles and documents

Synthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter

To identify selective high-affinity inhibitors of the vesicular acetylcholine transporter (VAChT), we have interposed a carbonyl group between the phenyl and piperidyl groups of the prototypical VAChT ligand vesamicol and its more potent analogues benzovesamicol and 5-aminobenzovesamicol. Of 33 compounds synthesized and tested, 6 display very high affinity for VAChT (K i, 0.25-0.66 nM) and greater than 500-fold selectivity for VAChT over σ1 and σ2 receptors. Twelve compounds have high affinity (Ki, 1.0-10 nM) and good selectivity for VAChT. Furthermore, 3 halogenated compounds, namely, trans-3-[4-(4-fluorobenzoyl) piperidinyl]-2-hydroxy-1,2,3,4-tetrahydronaphthalene (28b) (Ki = 2.7 nM, VAChT/sigma selectivity index = 70), trans-3-[4-(5-iodothienylcarbonyl) piperidinyl]-2-hydroxy-1,2,3,4-tetrahydronaphthalene (28h) (Ki = 0.66 nM, VAChT/sigma selectivity index = 294), and 5-amino-3-[4-(p-fluorobenzoyl) piperidinyl]-2-hydroxy-1,2,3,4,-tetrahydronaphthalene (30b) (Ki = 2.40 nM, VAChT/sigma selectivity index = 410) display moderate to high selectivity for VAChT. These three compounds can be synthesized with the corresponding radioisotopes so as to serve as PET/SPECT probes for imaging the VAChT in vivo.